ObjectiveThis paper aims to systematically summarize the construction methods and characteristics of Alzheimer's disease （AD） animal models， providing a reference for improving AD animal models. MethodsLiterature related to AD animal models published between January 2022 and April 2025 was retrieved from China National Knowledge Infrastructure （CNKI）， China Biomedical Literature Database （CBM）， Wanfang Data， and VIP Database. Information such as experimental animal species， month of age， sex， modeling methods， and period， as well as evaluation indicators， was collated， extracted， and imported into Microsoft Excel 2024 to establish the database. In addition， various modeling methods and detection means were summarized and compared. ResultsA total of 400 articles were included. Among the AD animal models， amyloid precursor protein/presenilin-1 （APP/PS1） mice were used most frequently， with a predominance of male animals. Typically， 3-4-month-old rats or 5-6-month-old mice were selected. The main modeling methods included natural aging， accelerated aging， surgical intervention， drug induction， and transgenic technology. The modeling period was mainly concentrated in a single day or 6-8 weeks. Detection indicators of the models focused on physiological， behavioral， pathological-morphological， and biochemical phenotypes. ConclusionThe construction methods of AD animal models are relatively mature， with multifactorial interventions effectively simulating human pathology， though certain limitations remain. By systematically reviewing and analyzing recent experimental literature of AD animal models， this study aims to provide theoretical support and a reference for further improving the construction of the AD animal model.

Lung transplantation is the optimal treatment for end-stage lung diseases and can significantly improve prognosis of the patients. However, postoperative complications such as infection, rejection, ischemia-reperfusion injury, and other challenges (like shortage of donor lungs) , limit the practical application of lung transplantation in clinical practice. Chinese research teams have been making continuous efforts and have achieved breakthroughs in basic research on lung transplantation by integrating emerging technologies and cutting-edge achievements from interdisciplinary fields, which has strongly propelled the development of this field. This article will comprehensively review the academic progress made by Chinese research teams in the field of lung transplantation in 2024, with a focus on the achievements of Chinese teams in basic research on lung transplantation. It aims to provide innovative ideas and strategies for key issues in the basic field of lung transplantation and to help China's lung transplantation cause reach a higher level.

Starting from the intrinsic relationship between the glymphatic system and the core pathogenesis of vascular cognitive impairment （VCI）， including internal dampness， phlegm turbidity， and blood stasis， this paper explores clinical approaches to the diagnosis and treatment of VCI. Dysfunction of the kidney's role in governing water leads to the accumulation of dampness， phlegm turbidity， and blood stasis， which are key pathological mechanisms underlying the onset and progression of VCI. The glymphatic system participates in the circulation of cerebrospinal fluid within the central nervous system， and its impairment can result in reduced clearance of soluble metabolic waste products in the brain， a crucial factor contributing to VCI. It is proposed that the "kidney governing water" function is related to the glymphatic system， and that the cerebral collaterals correspond structurally to the glymphatic pathways. Clinically， therapies aimed at tonifying the kidney， resolving phlegm， activating blood circulation， and unblocking collaterals， such as modified Kaixin Powder （开心散）， which eliminates dampness and turbidity， transforms phlegm， restores consciousness， enhances cognition， and strengthens the brain， are commonly employed. These treatments may improve VCI prognosis by regulating glymphatic system function， providing a theoretical basis for the prevention and treatment of VCI with traditional Chinese medicine.

Arsenic (organoarsenic) compound is one of the oldest drugs used by humans to treat various diseases. From its initial application in treating various skin diseases to the 1970s when arsenic trioxide (ATO) was proven to be able to significantly relieve acute promyelocytic leukemia (APL), arsenic (organoarsenic) compounds gradually occupied an important position in the history of medical development. This article reviews the pharmaceutical research progress of inorganic arsenic compounds and organic arsine compounds, covering anticancer, antiparasitic, antiviral and antibiotic aspects. It further explores the potential for developing new arsenic (organoarsenic) drugs with higher efficacy and lower toxicity, aiming to provide new research directions and ideas for the application of arsenic (organoarsenic) compounds in disease treatment.

Objective To investigate the relationship between kinase insert domain receptor(KDR)rs2305948 polymorphism and clopidogrel resistance(CR)in patients with acute coronary syndrome after receiving percutaneous coronary intervention(PCI).Methods A total of 468 patients with acute coronary syndrome,who were admitted to the Zhangjiakou Municipal First Hospital of China from September 2022 to September 2023,were selected as the subjects of study.All patients received PCI treatment and took medication of clopidogrel after the treatment.The occurrence of CR was recorded.The factors influencing the occurrence of CR were analyzed.The clinical significance of KDR rs2305948 polymorphism in predicting CR in patients with acute coronary syndrome after receiving PCI was evaluated.Results Of 468 patients with acute coronary syndrome,116(24.79％)developed CR.Logistic multivariate regression analysis indicated that low-density lipoprotein cholesterol(LDL-C,95％CI=1.420-8.390,OR=3.452),type 2 vascular endothelial growth factor receptor(VEGFR-2,95％CI=1.374-8.118,OR=3.340),KDR rs2305948 T/T genotype(95％CI=1.677-9.905,OR=4.076),and T allele(95％CI=1.390-8.207,OR=3.377)were the independent factors influencing the occurrence of CR inpatients with acute coronary syndrome after receiving PCI(all P＜0.05).Receiver operating characteristic(ROC)curve analysis showed that the sensitivity,specificity,and area under ROC curve(AUC)of the T/T genotype of KDR rs2305948 in predicting CR in patients with acute coronary syndrome after receiving PCI were 75.86％,70.45％,and 0.773(95％CI=0.666-0.880)respectively.Conclusion In patients with acute coronary syndrome after receiving PCI,the risk of developing CR is higher.The KDR rs2305948 polymorphism is correlated with CR in patients with acute coronary syndrome after receiving PCI,and it has a certain predictive value for CR.

Arsenic (organoarsenic) compound is one of the oldest drugs used by humans to treat various diseases. From its initial application in treating various skin diseases to the 1970s when arsenic trioxide (ATO) was proven to be able to significantly relieve acute promyelocytic leukemia (APL), arsenic (organoarsenic) compounds gradually occupied an important position in the history of medical development. This article reviews the pharmaceutical research progress of inorganic arsenic compounds and organic arsine compounds, covering anticancer, antiparasitic, antiviral and antibiotic aspects. It further explores the potential for developing new arsenic (organoarsenic) drugs with higher efficacy and lower toxicity, aiming to provide new research directions and ideas for the application of arsenic (organoarsenic) compounds in disease treatment.

BACKGROUND:Janus micro/nanoparticles are widely used in the field of tissue engineering,drug delivery,cancer therapy,bioimaging,and sensing due to their shape,structure,and functional anisotropy.OBJECTIVE:To elucidate the cutting-edge applications of Janus micro/nanoparticles in biomedicine.METHODS:Relevant literature published between 2010 and 2024 was retrieved from CNKI,WanFang Data,PubMed,and Web of Science databases.Searches were conducted using Chinese search terms"Janus nanoparticle,Janus particle,dual-faced particle,drug delivery,cancer therapy,bioimaging,biosensing,tissue engineering"and English search terms"Janus nanoparticle,Janus particle,drug delivery,cancer therapy,biosensing,bioimaging,tissue engineering."A total of 69 articles were selected for review after screening,organizing,summarizing,and synthesizing.RESULTS AND CONCLUSION:Janus micro/nanoparticles can be classified into three major categories based on their basic material properties:organic,inorganic,and organic-inorganic composites.Synthetic strategies consist of shielding,self-assembly,phase separation,microfluidics,and nucleation and growth techniques.Janus micro/nanoparticles exhibit high-efficiency drug delivery through characteristics such as high drug loading,gated release,and autonomous motion.In addition to enhancing traditional cancer treatment modalities(radiation and chemotherapy),Janus micro/nanoparticles can also be applied to emerging cancer treatment methods such as cell immunotherapy,protein drugs,and ferroptosis.Janus micro/nanoparticles serve as contrast agents to enhance bioimaging modalities(CT,MRI,and ultrasound)for high-quality imaging,guiding diagnosis and treatment.Janus micro/nanoparticles are utilized in tissue engineering for delivering growth factors,enhancing mechanical properties of biomaterials,and exhibiting antibacterial effects.Researchers have successfully tailored Janus micro/nanoparticles with desired functionalities by combining different organic polymers and inorganic materials using various synthetic strategies,enabling applications in complex biomedical fields.Despite current advancements,reports on the application of Janus micro/nanoparticles in tissue regeneration,large-scale production,and human clinical trials are relatively limited.Therefore,further research efforts are needed in the development,synthetic strategies,clinical safety assessment,and translation of such materials.

BACKGROUND:Janus micro/nanoparticles are widely used in the field of tissue engineering,drug delivery,cancer therapy,bioimaging,and sensing due to their shape,structure,and functional anisotropy.OBJECTIVE:To elucidate the cutting-edge applications of Janus micro/nanoparticles in biomedicine.METHODS:Relevant literature published between 2010 and 2024 was retrieved from CNKI,WanFang Data,PubMed,and Web of Science databases.Searches were conducted using Chinese search terms"Janus nanoparticle,Janus particle,dual-faced particle,drug delivery,cancer therapy,bioimaging,biosensing,tissue engineering"and English search terms"Janus nanoparticle,Janus particle,drug delivery,cancer therapy,biosensing,bioimaging,tissue engineering."A total of 69 articles were selected for review after screening,organizing,summarizing,and synthesizing.RESULTS AND CONCLUSION:Janus micro/nanoparticles can be classified into three major categories based on their basic material properties:organic,inorganic,and organic-inorganic composites.Synthetic strategies consist of shielding,self-assembly,phase separation,microfluidics,and nucleation and growth techniques.Janus micro/nanoparticles exhibit high-efficiency drug delivery through characteristics such as high drug loading,gated release,and autonomous motion.In addition to enhancing traditional cancer treatment modalities(radiation and chemotherapy),Janus micro/nanoparticles can also be applied to emerging cancer treatment methods such as cell immunotherapy,protein drugs,and ferroptosis.Janus micro/nanoparticles serve as contrast agents to enhance bioimaging modalities(CT,MRI,and ultrasound)for high-quality imaging,guiding diagnosis and treatment.Janus micro/nanoparticles are utilized in tissue engineering for delivering growth factors,enhancing mechanical properties of biomaterials,and exhibiting antibacterial effects.Researchers have successfully tailored Janus micro/nanoparticles with desired functionalities by combining different organic polymers and inorganic materials using various synthetic strategies,enabling applications in complex biomedical fields.Despite current advancements,reports on the application of Janus micro/nanoparticles in tissue regeneration,large-scale production,and human clinical trials are relatively limited.Therefore,further research efforts are needed in the development,synthetic strategies,clinical safety assessment,and translation of such materials.

Background::Although overnight fasting is recommended prior to endoscopic retrograde cholangiopancreatography (ERCP), the benefits and safety of high-carbohydrate fluid diet (CFD) intake 2 h before ERCP remain unclear. This study aimed to analyze whether high-CFD intake 2 h before ERCP can be safe and accelerate patients’ recovery.Methods::This prospective, multicenter, randomized controlled trial involved 15 tertiary ERCP centers. A total of 1330 patients were randomized into CFD group ( n = 665) and fasting group ( n = 665). The CFD group received 400 mL of maltodextrin orally 2 h before ERCP, while the control group abstained from food/water overnight (>6 h) before ERCP. All ERCP procedures were performed using deep sedation with intravenous propofol. The investigators were blinded but not the patients. The primary outcomes included postoperative fatigue and abdominal pain score, and the secondary outcomes included complications and changes in metabolic indicators. The outcomes were analyzed according to a modified intention-to-treat principle. Results::The post-ERCP fatigue scores were significantly lower at 4 h (4.1 ± 2.6 vs. 4.8 ± 2.8, t = 4.23, P <0.001) and 20 h (2.4 ± 2.1 vs. 3.4 ± 2.4, t= 7.94, P <0.001) in the CFD group, with least-squares mean differences of 0.48 (95% confidence interval [CI]: 0.26–0.71, P <0.001) and 0.76 (95% CI: 0.57–0.95, P <0.001), respectively. The 4-h pain scores (2.1 ± 1.7 vs. 2.2 ± 1.7, t = 2.60, P = 0.009, with a least-squares mean difference of 0.21 [95% CI: 0.05–0.37]) and positive urine ketone levels (7.7% [39/509] vs. 15.4% [82/533], χ2 = 15.13, P <0.001) were lower in the CFD group. The CFD group had significantly less cholangitis (2.1% [13/634] vs. 4.0% [26/658], χ2 = 3.99, P = 0.046) but not pancreatitis (5.5% [35/634] vs. 6.5% [43/658], χ2 = 0.59, P = 0.444). Subgroup analysis revealed that CFD reduced the incidence of complications in patients with native papilla (odds ratio [OR]: 0.61, 95% CI: 0.39–0.95, P = 0.028) in the multivariable models. Conclusion::Ingesting 400 mL of CFD 2 h before ERCP is safe, with a reduction in post-ERCP fatigue, abdominal pain, and cholangitis during recovery.Trail Registration::ClinicalTrials.gov, No. NCT03075280.

Objective:To investigate the prognostic value of enteroscopic grading for the prognostic assessment of patients with malignant hematological diseases who developed intestinal acute graft-versus-host disease (IT-aGVHD) after unrelated cord blood transplantation (UCBT) .Methods:Fifty patients with IT-aGVHD who developed hormone resistance after UCBT from June 2016 to June 2023 at Anhui Provincial Hospital were collected to compare the effective and survival rates of IT-aGVHD treatment in the group with milder enteroscopic mucosal injury (27 cases, enteroscopic grading of Ⅰ and Ⅱ) and the group with more severe injury (23 cases, enteroscopic grading of Ⅲ and Ⅳ) and to retrospectively analyze the factors affecting patients’ prognosis.Results:Patients in the mild and severe groups had an effective rate of 92.6% and 47.8% at 28 days after colonoscopy ( P<0.001), 81.5% and 39.1% at 56 days after colonoscopy ( P=0.002), with optimal effective rate of 92.6% and 65.2% ( P=0.040), respectively, and the differences were statistically significant. The multifactorial analysis found that enteroscopic grading was an independent risk factor affecting the effective rate of IT-aGVHD treatment. The overall survival rate at 2 years after colonoscopy was 70.4% (95% CI 52.0% -88.8% ) and 34.8% (95% CI 14.8% -54.8% ) for patients in the mild and severe groups, respectively, and the difference was statistically significant ( P=0.003). Multifactorial analysis revealed that enteroscopic grading, cytomegalovirus infection status, second-line treatment regimen, and patients’ age were independent risk factors for survival. Conclusion:The treatment efficacy and prognosis of patients in the group with less severe enteroscopic injury (grades Ⅰ and Ⅱ) were better than those in the group with more severe injury (grades Ⅲ and Ⅳ) .